Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a radiotherapy-based strategy compared with a radical prostatectomy-based approach, ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage ...
In the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from radiation therapy dose escalation (clinical progression free survival HR 0.19, 95% CI 0.05-0.70; p = 0.01 ...
ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...
Objectives This study aims to examine the association of time to recovery between early versus late presentation to ...
The data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal ... The most common adverse reactions (=25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse ...
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback